Postoperative Ocular Inflammation And Pain Therapeutics
1. Durezol patent expiration
Treatment: NA
DUREZOL IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US6114319 (Pediatric) | SANDOZ | Compositions containing difluprednate |
Nov, 2019
(6 years ago) | |
| US6114319 | SANDOZ | Compositions containing difluprednate |
May, 2019
(6 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 23, 2013 |
| New Indication(I-653) | Jun 13, 2015 |
| M(M-127) | Mar 22, 2016 |
| Pediatric Exclusivity(PED) | Sep 22, 2016 |
| Orphan Drug Exclusivity(ODE) | Jun 13, 2019 |
| Orphan Drug Exclusivity(ODE-26) | Jun 13, 2019 |
Drugs and Companies using DIFLUPREDNATE ingredient
NCE-1 date: 23 September, 2015
Market Authorisation Date: 23 June, 2008
Dosage: EMULSION
How can I launch a generic of DUREZOL before it's drug patent expiration?
More Information on Dosage
DUREZOL family patents
